Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Altimmune
Biotech
Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.
James Waldron
Jun 26, 2025 8:41am
Altimmune touts 'best-in-class' lean mass data in weight loss
Jun 23, 2024 1:45pm
Altimmune bails on hepatitis B after phase 2 data disappoint
Mar 27, 2024 7:57am
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am
Altimmune puts heart health at center of phase 2 obesity data
Dec 1, 2023 8:18am
Analyst sees path for Altimmune obesity drug despite stock drop
Mar 22, 2023 10:27am
